Protocol #0207-545: a phase I/II, escalating dose, open-label evaluation of safety, feasibility, and tolerability of transgenic lymphocyte immunization (TLI) vaccine subjects with histologically proven prostate adenocarcinoma.
Zanetti
Mauricio
M
University of California, San Diego, USA.
D024221:Antineoplastic Protocols; D019496:Cancer Vaccines; D002277:Carcinoma / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000628:therapy*
D019496:Cancer Vaccines